Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL.
Shi H, Zheng P, Liu R, Xu T, Yang F, Feng S, Guo Y, Ma L, Liu H, Lei Y, Li R, Deng B, Hou S, Li Y, Zheng Q, Hu K, Ke X.
Shi H, et al.
Blood Adv. 2023 Mar 28;7(6):1070-1075. doi: 10.1182/bloodadvances.2021006845.
Blood Adv. 2023.
PMID: 35901280
Free PMC article.
No abstract available.